Kabi Commands Respect As It Launches First Tocilizumab Biosimilar In Europe
Subcutaneous, Intravenous Forms ‘Will Transform Treatment Landscape’
Executive Summary
Fresenius Kabi has kicked off November by launching its tocilizumab biosimilar Tyenne – the first biosimilar to Actemra to reach the EU.